Vitroscope
Vitroscope provides an automated perfusion platform that keeps vascularized organoids, ex vivo tissues, and 3D bioprints viable for days under controlled flow, oxygen, pH, and temperature conditions. The benchtop system, vitro.alive, supports six parallel experiments with live-cell imaging and a browser-based digital twin interface for real-time monitoring and protocol control.
- Biotechnology
- Drug Discovery & Therapeutics
- Hardware
- Internet of Things
Funding
Raised to date
$8.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$7M across 2 disclosed rounds
AVCRCVDI+3$2M · Grant
Announced Nov 2026 · from article date
Disclosed cumulative: $7M
Reported total $8.8M
Incomplete round history. $1.8M of the $8.8M reported total isn’t matched to a known round.
Founders
Founder details are not available yet.
Product
Problem
Traditional cell culture methods rely on static conditions that fail to replicate the dynamic, perfused microenvironment of living tissue, limiting the physiological relevance of in vitro models. Researchers studying vascularised organoids, ex vivo tissue slices, and 3D bioprints struggle to maintain tissue viability and function over extended periods, hindering drug discovery and disease modeling.
Solution
Vitroscope provides an integrated perfusion platform that brings controlled flow to vascularised organoids, ex vivo tissues, and 3D bioprints, preserving the native microenvironment for extended culture periods. The system measures and controls gas mixture (CO₂, O₂, H₂), temperature, and flow rate, enabling repeatable physiological culture conditions. A browser-based digital twin interface allows researchers to define experiment conditions, schedule screening runs, monitor progress, and acquire longitudinal microscopy images in real time. The platform supports tissue, 2D cultures, mechanobiology, organoids, and 3D bioprints, and is compatible with upstream and downstream screening workflows.
Target Audience
Primary customers are academic research institutions, pharmaceutical companies, and contract research organizations conducting drug discovery, disease modeling, and tissue engineering research using organoids, ex vivo tissue, or 3D bioprints.
Features
- Closed-loop flow channels in well-plate format with physiological flow control for vascular network integration and multi-organ system modeling
- Real-time gas control (CO₂, O₂, H₂) for hypoxia and hyperoxia studies, plus temperature regulation
- Browser-based digital twin interface with custom protocol library, fleet management, and real-time monitoring
- Dynamic imaging capabilities for longitudinal observation at molecule resolution
- Sensor-extended imaging platform enabling iterative perturbation-to-measurement workflows
- Portable, zero-footprint standalone design requiring minimal training
- Supports six independent parallel experiments on the benchtop vitro.alive platform, with a higher-throughput vitro.scale system in development for 96 parallel experiments